183 related articles for article (PubMed ID: 34119073)
1. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil.
Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I
Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723
[TBL] [Abstract][Full Text] [Related]
3. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
Bitetti I; Lanzara V; Margiotta G; Varone A
Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
[TBL] [Abstract][Full Text] [Related]
4. Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1.
Nanri D; Yuge K; Goto K; Kimura T; Yae Y; Mizuochi T; Sato R; Itonaga T; Maeda T; Yamashita Y
Kurume Med J; 2024 May; 69(3.4):255-259. PubMed ID: 38233181
[TBL] [Abstract][Full Text] [Related]
5. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
[TBL] [Abstract][Full Text] [Related]
6. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry.
Servais L; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Proud CM; Shieh PB; Tizzano EF; Quijano-Roy S; Desguerre I; Saito K; Faulkner E; Benguerba KM; Raju D; LaMarca N; Sun R; Anderson FA; Finkel RS
J Neuromuscul Dis; 2024; 11(2):425-442. PubMed ID: 38250783
[TBL] [Abstract][Full Text] [Related]
7. [Experience of the treatment of spinal muscular atrophy type 3 Kugelberg-Welander with Nusinersen].
Shchepankevich LA; Ushkalenko VK; Dolotov KA; Maksimova YV; Veretelnikov IA; Taneeva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4):153-158. PubMed ID: 38676690
[TBL] [Abstract][Full Text] [Related]
8. Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio.
Waldrop MA; Chagat S; Storey M; Meyer A; Iammarino M; Reash N; Alfano L; Lowes L; Noritz G; Prochoroff A; Rossman I; Ginsberg M; Mosher K; Broomall E; Bass N; Gushue C; Kotha K; Paul G; Shell R; Tsao CY; Mendell JR; Connolly AM
Neuromuscul Disord; 2024 Jan; 34():41-48. PubMed ID: 38142474
[TBL] [Abstract][Full Text] [Related]
9. Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports.
Mizuno T; Kanouchi T; Tamura Y; Hirata K; Emoto R; Suzuki T; Kashimada K; Morio T
BMC Neurol; 2023 Oct; 23(1):392. PubMed ID: 37907848
[TBL] [Abstract][Full Text] [Related]
10. Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children.
Chencheri N; Alexander G; Nugud A; Majadas E; Salim H; Prudhomme K; DeJager N; Janardhanan VS; Elbashir H
Muscle Nerve; 2023 Sep; 68(3):269-277. PubMed ID: 37392188
[TBL] [Abstract][Full Text] [Related]
11. Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment.
Nigro E; Grunebaum E; Kamath B; Licht C; Malcolmson C; Jeewa A; Campbell C; McMillan H; Chakraborty P; Tarnopolsky M; Gonorazky H
Front Neurol; 2023; 14():1230889. PubMed ID: 37780708
[TBL] [Abstract][Full Text] [Related]
12. Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.
Gaillard J; Gu AR; Neil Knierbein EE
J Pediatr; 2023 Sep; 260():113493. PubMed ID: 37211209
[TBL] [Abstract][Full Text] [Related]
13. Dysphagia Phenotypes in Spinal Muscular Atrophy: The Past, Present, and Promise for the Future.
McGrattan KE; Graham RJ; DiDonato CJ; Darras BT
Am J Speech Lang Pathol; 2021 May; 30(3):1008-1022. PubMed ID: 33822657
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: A systematic review with meta-analysis.
Fernandes BD; Krug BC; Rodrigues FD; Cirilo HNC; Borges SS; Schwartz IVD; Probst LF; Zimmermann I
PLoS One; 2024; 19(5):e0302860. PubMed ID: 38713659
[TBL] [Abstract][Full Text] [Related]
15. Vaccination proposal for patients on onasemnogene abeparvovec therapy.
Dobner S; Kulcsár A; Liptai Z; Vojnisek Z; Constantin T; Szabó L
Eur J Paediatr Neurol; 2024 Mar; 49():95-99. PubMed ID: 38457958
[TBL] [Abstract][Full Text] [Related]
16. Sleep disordered breathing in infants identified through newborn screening with spinal muscular atrophy.
Chiang J; Xiao L; Nigro E; St-Laurent A; Weinstock L; Law E; Janevski J; Kuyntjes S; Cithiravel N; Tran T; Wolter NE; Gonorazky H; Amin R;
Sleep Med; 2023 Nov; 111():161-169. PubMed ID: 37778092
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies.
Motta-Santos A; Noronha K; Reis C; Freitas D; Carvalho L; Andrade M
Value Health Reg Issues; 2024 Apr; 42():100985. PubMed ID: 38669792
[TBL] [Abstract][Full Text] [Related]
18. Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment.
Menduti G; Rasà DM; Stanga S; Boido M
Front Pharmacol; 2020; 11():592234. PubMed ID: 33281605
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England.
Weidlich D; Servais L; Kausar I; Howells R; Bischof M
Neurol Ther; 2023 Aug; 12(4):1205-1220. PubMed ID: 37222861
[TBL] [Abstract][Full Text] [Related]
20. Motor and neurocognitive profiles of children with symptomatic spinal muscular atrophy type 1 with two copies of
Bitetti I; Manna MR; Stella R; Varone A
Front Neurol; 2024; 15():1326528. PubMed ID: 38450080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
